Rivastigmine 3M Health Care Ltd

RSS

rivastigmine

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Rivastigmine 3M Health Care Ltd has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 18/09/2014

Authorisation details

Product details
Name
Rivastigmine 3M Health Care Ltd
Agency product number
EMEA/H/C/003824
Active substance
rivastigmine
International non-proprietary name (INN) or common name
rivastigmine
Therapeutic area (MeSH)
Alzheimer Disease
Anatomical therapeutic chemical (ATC) code
N06DA03
Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic medicines.

Publication details
Marketing-authorisation holder
3M Health Care Limited
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
03/04/2014
Contact address
1 Morley Street
Loughborough
Leicestershire
LE11 1EP
United Kingdom

Product information

19/08/2014 Rivastigmine 3M Health Care Ltd - EMEA/H/C/003824 -

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Transdermal patch

Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Assessment history

How useful was this page?

Add your rating